Suggested remit: To appraise the clinical and cost effectiveness of inebilizumab within its marketing authorisation for treating neuromyelitis optica spectrum disorders.
Please note this appraisal has now been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- STA Standard
- ID number:
- 1529
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 January 2024 | Discontinued. Please note this appraisal has now been discontinued. |
| 03 April 2020 | In progress. Topic is in progress |
| 03 April 2020 | Note added to the project documents |
| 02 September 2019 (14:00) | Scoping workshop (Manchester) |
| 18 July 2019 - 15 August 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual